ArticleJournal of nanobiotechnology2026
A facile polysaccharide hydrogel activates PPARγ via the Gut-Kidney axis to ameliorate chronic kidney disease.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Biomedical Hydrogels Based on Natural Polysaccharides: Structural Design.Gels (Basel, Switzerland) · 2026Review
- Herbal polysaccharides-a rising star in engineering multifunctional biomaterials for tissue repair and regeneration.Regenerative biomaterials · 2026Review
- Programmed Cell Death: A Key Mechanism of Traditional Chinese Medicine in the Treatment of Membranous Nephropathy.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Chronic Kidney Disease (CKD) features gut microbiota dysbiosis, systemic inflammation, and impaired barrier function. The formation of such a triad of "microbiota-metabolite-barrier" dysregulation underscores the therapeutic potential of a Gut-Kidney Axis intervention strategy. Traditional Chinese medicine highlights plant-derived polysaccharides as renoprotective modulators of the Gut-Kidney Axis, yet free polysaccharides suffer from limited colonic exposure, single-function delivery, and proximal-skewed fermentation. Thus, this study engineered a Morinda officinalis polysaccharide (MOPs)/Inulin composite hydrogel (MI Gel) via a simple, green hydrothermal process to achieve colon-targeted, sustained release with mucosal adhesion for CKD therapy via the Gut-Kidney Axis. This hydrogel exhibited degradation resistance and prolonged retention in the intestinal tract of CKD model mice, while effectively reshaping the gut microbiota community structure by increasing the abundance of Muribaculaceae and Allobaculum, elevating serum propionate and butyrate levels, and activating GPCRs and PPARγ signaling pathways. As a result, the gel treatment reduced the levels of intestinal inflammatory cytokines (TNF-α, IL-6, and IL-1β) and reactive oxygen species (ROS). MI Gel further improved glomerular function and attenuated renal fibrosis compared to free polysaccharides. This colon-targeted, acid-resistant platform utilizes synergistic fermentation of MOPs and Inulin to restore Gut-Kidney Axis homeostasis, providing a viable long-term approach for CKD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.